Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
This Week in Biotech
Latest
Top
Discussions
CEPI Rescues Moderna’s Bird Flu Vaccine and Takeda’s Delivers in Psoriasis — This Week in Biotech #82
From pandemic preparedness to late stage clinical wins, plus key FDA approvals and trial readouts that will shape 2026 (Dec 12-18, 2025).
Dec 19
•
Katerina Roznik
1
1
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Plus Biohaven’s next-gen Trop2 data, Kymera’s STAT6 surge, AC Immune’s Parkinson’s signal, Mirum’s hepatitis delta bet, the CDC’s new Covid vaccine…
Dec 12
•
Katerina Roznik
1
FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80
Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec…
Dec 5
•
Katerina Roznik
7
2
3
CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins — This Week in Biotech #79
Plus Arrowhead’s first approval, Abbott buys Exact Sciences, Merck bets $9.2B on flu prevention, and fresh takeover buzz in gene editing and IBD (Nov…
Nov 21
•
Katerina Roznik
9
2
FDA Opens New Pathway and Biotech’s Return to Offense — This Week in Biotech #78
A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins (Nov 7-13, 2025).
Nov 14
•
Katerina Roznik
4
2
1
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77
Politics, pricing, and pipelines collide. From GLP-1 wars and TrumpRx to Moderna’s refocus and J&J’s Caplyta win (Oct 31-Nov 6, 2025).
Nov 7
•
Katerina Roznik
4
2
2
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
Plus Novartis bets $12B on RNA delivery; Intensity’s tumor injection therapy stuns with 400% stock surge, and BridgeBio cements rare-disease momentum…
Oct 31
•
Katerina Roznik
6
1
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75
ICER flags +51% net launch prices, Novo board shake-up, Tecentriq’s ctDNA-guided bladder success, Exelixis OS bump in colorectal cancer, and Ideaya…
Oct 24
•
Katerina Roznik
5
3
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74
Plus: BioCryst-Astria rounds out HAE, Praxis’ essential tremor pill succeeds in Phase 3, and Rocket’s LAD-I gene therapy returns to FDA review (Oct…
Oct 17
•
Katerina Roznik
5
1
Novo Nordisk Buys Akero & Regeneron’s Libtayo Wins Adjuvant CSCC Nod — This Week in Biotech #73
Repatha $239 cash launch, Dyne’s DM1 gains, Skye’s CB1 combo signal, Novavax-Sanofi EU handoff, Humacyte data + financing, Rocket pulls FA gene therapy…
Oct 10
•
Katerina Roznik
5
1
Pharma Tariffs on Ice, FDA Limits Filings, Amgen’s PCSK9 Win — This Week in Biotech #72
Plus $8B Genmab-Merus deal, Metsera's monthly GLP-1 score, Novavax/Sanofi & Vaxcyte/Thermo shore up U.S. capacity, and AbbVie sets U.K. Elahere price to…
Oct 3
•
Katerina Roznik
4
1
1
Trump’s 100% Drug Tariff and a Huntington’s Breakthrough — This Week in Biotech #71
Palsonify cleared, Evkeeza label expanded, uniQure slows HD by ~75%, Pfizer buys Metsera, Cidara accelerates flu trial, ACIP shifts COVID guidance (Sept…
Sep 26
•
Katerina Roznik
2
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
